Global Breast Cancer Therapeutics Market Report and Forecast 2023-2031
Global Breast Cancer Therapeutics Market Outlook:
The global breast cancer therapeutics market size was USD 30.2 billion in 2022, driven by the rising incidence of breast cancer across the globe. The market size is anticipated to grow at a CAGR of 10.8% during the forecast period of 2023-2031 to achieve a value of USD 75.8 billion by 2031.
Breast Cancer Therapeutics: Introduction
Breast cancer is a complex and devastating disease that affects millions of women worldwide. It is the most common cancer among women, with a significant impact on their health, well-being, and overall quality of life. The field of breast cancer therapeutics plays a crucial role in diagnosing, treating, and managing this disease.
The introduction of breast cancer therapeutics has revolutionized the way we approach the treatment of this condition. The development of various treatment modalities, including surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy, has provided healthcare professionals with a diverse arsenal of options to combat breast cancer.
The market for breast cancer therapeutics is driven by several factors. Firstly, the rising incidence of breast cancer, coupled with the growing awareness and early detection efforts, has led to an increased demand for effective treatment options. Secondly, advancements in medical research and technology have resulted in the discovery of new therapeutic targets and the development of more precise and targeted treatments. Thirdly, there is a continuous focus on improving patient outcomes, reducing treatment-related side effects, and enhancing the overall quality of life for breast cancer patients.
Key Trends in the Breast Cancer Therapeutics Market
Some key trends involved in the breast cancer therapeutics market are:
- Targeted Therapies: There is a growing focus on targeted therapies in the field of breast cancer treatment. These therapies specifically target the molecular characteristics of a tumor, such as specific receptors or genetic mutations, to inhibit tumor growth and improve treatment outcomes. Targeted therapies have shown promising results in subtypes of breast cancer, such as HER2-positive and hormone receptor-positive breast cancer.
- Immunotherapy: Immunotherapy is emerging as a key trend in breast cancer treatment. It involves stimulating the body's immune system to recognize and attack cancer cells. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, are being studied in clinical trials for their potential to enhance the immune response against breast cancer. Immunotherapy offers the potential for durable responses and long-term survival benefits.
- Personalized Medicine: The concept of personalized medicine is gaining traction in breast cancer treatment. With advances in genomic profiling, clinicians can identify specific genetic alterations in tumors and tailor treatment strategies accordingly. This approach aims to optimize treatment efficacy while minimizing unnecessary side effects. Personalized medicine also encompasses the use of biomarkers to predict treatment response and guide therapy selection.
Breast Cancer Therapeutics Market Segmentations
Market Breakup by Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastazumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
- Chemotherapy
- Taxanes
- Anthracyclines
- Anti-Metabolites
- Alkylating Agents
- Epothilones
- Immunotherapy
- Hormone Receptor
- HER2+
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Oral
- Injectables
- Hospitals
- Homecare
- Specialty Clinics
- Others
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Breast Cancer Therapeutics Market Scenario
Breast cancer therapeutics form a critical component of the healthcare industry, aiming to diagnose, treat, and manage one of the most prevalent forms of cancer affecting women worldwide. The market for breast cancer therapeutics is driven by the rising incidence of breast cancer, advancements in diagnostic techniques, and the continuous pursuit of more effective treatment options.
The global market for breast cancer therapeutics is characterized by a wide range of treatment modalities, including surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Each treatment modality plays a specific role in the management of breast cancer, with the choice depending on the stage, subtype, and individual patient characteristics.
Patient-centric care and personalized medicine are key trends in the breast cancer therapeutics market. Healthcare providers are increasingly focused on tailoring treatment strategies to individual patients, considering factors such as genetic profiles, tumour characteristics, and patient preferences. This personalized approach aims to optimize treatment outcomes and minimize potential side effects.
Furthermore, the market is witnessing an increased emphasis on supportive care and survivorship programs for breast cancer patients. This includes initiatives to manage treatment-related side effects, provide psychological support, and enhance the overall quality of life for survivors.
Breast Cancer Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Genentech, Inc.
- Eli Lilly and Company
- Novartis AG
- AstraZeneca
- Sanofi
- Fresenius Kabi
- Astellas Pharma Inc.
- Oncothyreon Inc
- Genzyme Corporation
- F. Hoffman-La Roche Pvt. Ltd
- AbbVie, Inc.
- MacroGenics Inc.
- Onyx Pharmaceuticals, Inc.
- BioNumerik Pharmaceuticals Inc.
- Celldex Therapeutics.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Breast Cancer Therapeutics Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Breast Cancer Epidemiology Analysis
- 5.1 Epidemiology Overview (2016-2031)
- 5.2 North America Breast Cancer Epidemiology (2016-2031)
- 5.3 Europe Breast Cancer Epidemiology (2016-2031)
- 5.4 Asia-Pacific Breast Cancer Epidemiology (2016-2031)
- 5.5 Latin America Breast Cancer Epidemiology (2016-2031)
- 5.6 Middle East & Africa Breast Cancer Epidemiology (2016-2031)
- 6 Global Breast Cancer Therapeutics Market Overview
- 6.1 Global Breast Cancer Therapeutics Market Historical Value (2016-2022)
- 6.2 Global Breast Cancer Therapeutics Market Forecast Value (2023-2031)
- 7 Global Breast Cancer Therapeutics Market Landscape
- 7.1 Breast Cancer Therapeutics: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Breast Cancer Therapeutics: Product Landscape
- 7.2.1 Analysis by Therapy
- 7.2.2 Analysis by Cancer Type
- 7.2.3 Analysis by Distribution Channel
- 7.2.4 Analysis by Route of Administration
- 7.2.5 Analysis by End User
- 8 Breast Cancer Therapeutics Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Global Breast Cancer Therapeutics Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Global Breast Cancer Therapeutics Market Segmentation
- 11.1 Global Breast Cancer Therapeutic Market by Therapy
- 11.1.1 Market Overview
- 11.1.2 Targeted Therapy
- 11.1.2.1 Abemaciclib
- 11.1.2.2 Ado-Trastuzumab Emtansine
- 11.1.2.3 Everolimus
- 11.1.2.4 Trastazumab
- 11.1.2.5 Ribociclib
- 11.1.2.6 Palbociclib
- 11.1.2.7 Pertuzumab
- 11.1.2.8 Olaparib
- 11.1.3 Hormonal Therapy
- 11.1.3.1 Selective Estrogen Receptor Modulators (SERMs)
- 11.1.3.2 Aromatase Inhibitors
- 11.1.3.3 Estrogen Receptor Downregulators (ERDs)
- 11.1.4 Chemotherapy
- 11.1.4.1 Taxanes
- 11.1.4.2 Anthracyclines
- 11.1.4.3 Anti-Metabolites
- 11.1.4.4 Alkylating Agents
- 11.1.4.5 Epothilones
- 11.1.5 Immunotherapy
- 11.2 Global Breast Cancer Therapeutic Market by Cancer Type
- 11.2.1 Market Overview
- 11.2.2 Hormone Receptor
- 11.2.3 HER2+
- 11.3 Global Breast Cancer Therapeutic Market by Distribution Channel
- 11.3.1 Market Overview
- 11.3.2 Hospital Pharmacies
- 11.3.3 Retail Pharmacies
- 11.3.4 Online Pharmacies
- 11.3.5 Others
- 11.4 Global Breast Cancer Therapeutic Market by Route of Administration
- 11.4.1 Market Overview
- 11.4.2 Oral
- 11.4.3 Injectables
- 11.5 Global Breast Cancer Therapeutic Market by End User
- 11.5.1 Market Overview
- 11.5.2 Hospitals
- 11.5.3 Homecare
- 11.5.4 Specialty Clinics
- 11.5.5 Others
- 11.6 Global Breast Cancer Therapeutics Market by Region
- 11.6.1 Market Overview
- 11.6.2 North America
- 11.6.3 Europe
- 11.6.4 Asia Pacific
- 11.6.5 Latin America
- 11.6.6 Middle East and Africa
- 12 North America Breast Cancer Therapeutics Market
- 12.1 Market Share by Country
- 12.2 United States of America
- 12.3 Canada
- 13 Europe Breast Cancer Therapeutics Market
- 13.1 Market Share by Country
- 13.2 United Kingdom
- 13.3 Germany
- 13.4 France
- 13.5 Italy
- 13.6 Others
- 14 Asia Pacific Breast Cancer Therapeutics Market
- 14.1 Market Share by Country
- 14.2 China
- 14.3 Japan
- 14.4 India
- 14.5 ASEAN
- 14.6 Australia
- 14.7 Others
- 15 Latin America Breast Cancer Therapeutics Market
- 15.1 Market Share by Country
- 15.2 Brazil
- 15.3 Argentina
- 15.4 Mexico
- 15.5 Others
- 16 Middle East and Africa Breast Cancer Therapeutics Market
- 16.1 Market Share by Country
- 16.2 Saudi Arabia
- 16.3 United Arab Emirates
- 16.4 Nigeria
- 16.5 South Africa
- 16.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 INDIA CDSCO
- 17.1.4 JAPAN PMDA
- 17.1.5 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Application
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Partnership and Collaborations Analysis
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Genentech, Inc.
- 23.1.1 Financial Analysis
- 23.1.2 Product Portfolio
- 23.1.3 Demographic Reach and Achievements
- 23.1.4 Mergers and Acquisitions
- 23.1.5 Certifications
- 23.2 Eli Lilly and Company
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Novartis AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 AstraZeneca
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Sanofi
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Fresenius Kabi
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Astellas Pharma Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Oncothyreon Inc
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Genzyme Corporation
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 F. Hoffman-La Roche Pvt. Ltd
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 AbbVie, Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 23.12 MacroGenics Inc.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Mergers and Acquisitions
- 23.12.5 Certifications
- 23.13 Onyx Pharmaceuticals, Inc.
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Mergers and Acquisitions
- 23.13.5 Certifications
- 23.14 BioNumerik Pharmaceuticals Inc.
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Mergers and Acquisitions
- 23.14.5 Certifications
- 23.15 Celldex Therapeutics.
- 23.15.1 Financial Analysis
- 23.15.2 Product Portfolio
- 23.15.3 Demographic Reach and Achievements
- 23.15.4 Mergers and Acquisitions
- 23.15.5 Certifications
- 24 Breast Cancer Therapeutics - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
- 26.1 Very Small Companies
- 26.2 Small Companies
- 26.3 Mid-Sized Companies
- 26.4 Large Companies
- 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
- 27.1 Government Funded
- 27.2 Private Insurance
- 27.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook